32 results about "Ubiquitin-conjugating enzyme" patented technology

An isolated nucleic acid molecule encoding human skeletal muscle-specific ubiquitin-conjugating enzyme and comprising a nucleotide sequence coding for the amino acid sequence shown in SEQ ID NO:22 is disclosed. The isolation of this molecule makes it possible to detect its expression in various tissues, analyze its structure and function, and produce the human proteins encoded by this molecule by the technology of genetic engineering. In this way, it is possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the molecule, for example hereditary diseases and cancer, and diagnose and treat such diseases.

The present invention relates to the diagnosis of breast cancer. It discloses the use of ubiquitin-conjugating enzyme E2N (UBC13) in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring UBC13 in the sample. Measurement of UBC13 can, e.g., be used in the early detection or diagnosis of breast cancer.

The invention discloses a fenneropenaeus chinensis ubiquitin-conjugating enzyme gene with a nucleotide sequence expressed as SEQ ID No. 1, and provides a recombinant expression and purification method thereof. The invention also provides ubiquitin-conjugating enzyme coded by the fenneropenaeus chinensis ubiquitin-conjugating enzyme gene, wherein the amino acid sequence of the ubiquitin-conjugating enzyme is expressed as SEQ ID No. 2; and the invention provides application of the gene sequence and application of the ubiquitin-conjugating enzyme, namely the fenneropenaeus chinensis ubiquitin-conjugating enzyme gene can be used for preparing a prokaryotic expression vector, transforming escherichia coli and expressing recombinant protein with antiviral activity. The recombinant ubiquitin-conjugating enzyme protein obtained by using the invention can be used for antiviral feed additive, animal and plant gene transformation and medicament development.

The invention discloses a kit for detecting a ubiquitin-binding enzyme antibody and a use method, and belongs to the field of biomedicine. The kit for detecting the ubiquitin-binding enzyme antibody comprises: a solution for detecting the ubiquitin-binding enzyme antibody; and the solution comprises an active ester for labeling a ubiquitin-binding enzyme antibody and a non-radioactive solution. The active ester comprises thioruthenium derivative active ester and biotin polyethylene glycol active ester. The kit further comprises a 96-well plate, a streptavidin graphene plate, a 0.01 mol/L PB, a 5% BSA solution and a PBST solution. The streptavidin graphene flat plate is an MSD96 pore plate marked by streptomycin. Compared with the prior art, the kit provided by the invention has the advantages of higher sensitivity and specificity, no use of radioactive substances, simplicity and convenience in operation, capability of detecting the amount of antibodies in trace serum, and very good clinical application value.

The present invention provides a rabbit anti-cucumber ubiquitin-conjugating enzyme CsE2 protein polyclonal antibody and a preparation method thereof. The method comprises: extracting ubiquitin-conjugating enzyme CsE2 protein from cucumber stem apex; carrying out two-dimensional electrophoresis, and purifying to obtain antigen; injecting the antigen into rabbits to immunize; and drawing serum, and purifying to obtain the final rabbit anti-cucumber ubiquitin-conjugating enzyme CsE2 protein polyclonal antibody. According to the present invention, The prepared rabbit anti-cucumber ubiquitin-conjugating enzyme CsE2 protein polyclonal antibody has characteristics of good specificity and high purity, can be subjected to specific binding reaction with cell endogenous cucumber ubiquitin-conjugating enzyme CsE2 protein, can meet requirements of immunohistochemistry, immunoblotting and other experiments, and can be used for establishment of in vitro immunoassays; and the preparation method provides the important tool for the deep research of the biological functions of the cucumber ubiquitin-conjugating enzyme CsE2 protein and the identification of the cucumber plant dwarf, and has important theoretical significance and practical application values.

The invention discloses a planthopper lethal gene segment. The planthopper lethal gene segment ubiquitin-conjugating enzyme morgue capable of leading to planthopper death after interference and with the sequence shown as SEQ ID NO.1 is screened out. When dsRNA of the gene segment is utilized and fed to small brown rice planthoppers and brown planthoppers, the death of the small brown rice planthoppers and brown planthoppers can be effectively caused. The planthopper lethal gene segment disclosed by the invention is safety to environment, ecology and food, and a novel path is provided for utilizing an RNA interference technology to control injurious insects.

The present invention provides methods for identifying compounds that selectively bind one or more active sites within an ubiquitin conjugating enzyme. The compounds identified by the methods are useful in the treatment of disorders attributed to dysregulated ubiquitin conjugating enzyme function, specifically in hyperproliferative disorders.

Methods and compositions disclosed herein generally relate to compositions and methods for suppressing hematopoietic stem and progenitor cells (HSPCs) and the treatment of diseases or disorders involving UBE2N, such as cancers, including disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) and chronic inflammatory disorders. Particular aspects relate to treating, e.g. acute myelomonocytic leukemia (AML-M4) and acute monocytic leukemia (AML-M5). Particular aspects of the invention relate to determining an individual in need of treatment who can be treated with a UBE2N inhibitor, such as an individual having AML-M4 and/or AML-M5. The invention further relates to using a UBE2N inhibitor to treat a disease or disorder characterized by malignant hematopoietic cells, as well as other cancers, and chronic inflammatory disorders, and as immune checkpoint regulators.

The invention discloses a hybrid tumor DY01 of a monoclonal antibody of a human ubiquitin-conjugating enzyme UbcH10, and the monoclonal antibody. The hybrid tumor DY01 of the monoclonal antibody of the human ubiquitin-conjugating enzyme UbcH10 is collected in China General Microbiological Culture Collection Center on Nov. 19, 2010 with the collection number of CGMCC No.4334. The monoclonal antibody generated can specifically combine the natural human ubiquitin-conjugating enzyme UbcH10. The antibody can be used for enzyme-linked immuno sorbent assay (ELISA), western-blot, cell immunofluorescence and immunohistochemical dyeing study of clinical tissue specimens. Meanwhile, the antibody can be used for preparing an immunodetection reagent for detecting the expression condition of the human ubiquitin-conjugating enzyme UbcH10 in laboratories and clinically.

Provided are methods of treating or preventing Ca²⁺/calmodulin-dependent kinase II (CaMKII)-mediated diseases, methods of alleviating cardiac injury, methods of stimulating the activity of ubiquitin-conjugating enzyme, methods of preventing degradation of ubiquitin-conjugating enzyme, methods of preventing cardiomyocyte death, methods of reducing DNA damage in a cell, methods for diagnosing CaMKII-mediated diseases, kits for diagnosing CaMKII-mediated diseases, biomarkers for diagnosing a CaMKII-mediated disease, and use of CaMKIIδ9 as a biomarker for diagnosing a CaMKII-mediated disease. Also provided herein are methods for identifying molecules, isolated polypeptides, isolated nucleic acids, and antagonists thereof.

The invention discloses a human ubiquitin-conjugating enzyme UbcH10 monoclonal antibody hybrid tumor DY03 and a monoclonal antibody. The human ubiquitin-conjugating enzyme UbcH10 monoclonal antibody hybrid tumor DY03 is collected in the China General Microbiological Culture Collection Center (CGMCC) with the collection number of CGMCC No.4336 on November 19, 2010. The produced monoclonal antibody can be specifically recombined with a natural human ubiquitin-conjugating enzyme UbcH10 protein and can be applied to ELISA (Enzyme-Linked Immuno Sorbent Assay), western-blot, cell immunofluorescence and immune tissue chemical staining research of clinical tissue samples. Meanwhile, the antibody can be prepared into an immunodetection reagent for laboratory and clinical detection of the expression situation of the human ubiquitin-conjugating enzyme UbcH10.

The present invention relates to a small molecule inhibitor of ubiquitin-binding enzyme E2T (UBE2T) and use thereof in the treatment of cancer.

A polynucleotide isolated from cotton plants capable of initiating transcription and with sequence identity to SEQ ID No.1 is provided. In some aspects, the polynucleotide has sequence identity to SEQ ID No. 1 of at least 40%, is the reverse complement or the reverse of such sequences. In some aspects, the polynucleotide is linked to expression enhancers or sequences of interest. In some embodiments, a recombinant vector comprises the polynucleotide. In some aspects, the recombinant vector comprises enhancers, termination sequences, or sequences of interest. In some embodiments a transformed cell, plant, plant part, or propagulum comprise the polynucleotide.

The present invention describes a newly discovered ubiquitin conjugating enzyme homologue, called RATL1d6 herein, and its encoding polynucleotide, isolated and identified from activated T lymphocytes. Also described are expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies associated with the activity and use of the newly-discovered polynucleotide and/or polypeptide of the present invention. Methods for treating, diagnosing, preventing and screening for disorders related to the expression of the RATL1d6 ubiquitin conjugating enzyme polypeptide are described.